John Anderson, MD

Anderson discusses recent advancements in CGM technology, as well as the myriad behavioral and clinical benefits of CGM use in T2D with or without insulin.

Experts discuss potential barriers to screening for hypercortisolism in primary care and specialty settings, ways to address these barriers, when a patient should be referred to endocrinology after screening, and how primary care clinicians and specialists can collaborate effectively to identify, screen, and refer patients with hypercortisolism to optimize patient care.

Experts discuss the role of primary care clinicians in identifying and screening patients for hypercortisolism, how hypercortisolism affects mental health and how primary care clinicians can identify at-risk patients, and how hypercortisolism contributes to osteoporosis and an increased risk of fractures.

Experts discuss how hypercortisolism contributes to treatment-resistant hypertension and other cardiovascular diseases, the impact of treating hypercortisolism on cardiovascular risks, when cardiologists should suspect hypercortisolism as a contributing factor to cardiovascular disease, the role of hypercortisolism in type 2 diabetes, how it complicates the management of type 2 diabetes and impacts long-term glucose control, and when endocrinologists should suspect hypercortisolism in their patients with type 2 diabetes.

Experts discuss risk factors and laboratory abnormalities that might raise clinical suspicion for hypercortisolism and who should be screened for hypercortisolism.

Experts discuss risk factors and laboratory abnormalities that might raise clinical suspicion for hypercortisolism and who should be screened for hypercortisolism

Experts discuss how the clinical presentation of hypercortisolism differs in the primary care vs specialist setting, highlighting earlier signs/symptoms vs overt disease, and review recent data on the prevalence of hypercortisolism, including its higher occurrence in patients with difficult-to-control diabetes, difficult-to-control hypertension, and cardiovascular disease.

Experts discuss how hypercortisolism affects health care utilization and costs for patients, comparing it with patients with other chronic diseases, and how our understanding of the clinical presentation of hypercortisolism has evolved, distinguishing overt hallmark symptoms from nonspecific features overlapping with chronic disease.

Experts discuss the challenges of identifying and diagnosing hypercortisolism, the reasons behind its often-delayed diagnosis, the impact of a wide spectrum of clinical signs and symptoms on clinicians’ ability to diagnose the condition, and recent data on the prevalence of hypercortisolism in at-risk populations, including those with difficult-to-control diabetes, hypertension, and cardiovascular disease.

Experts discuss the long-term health impacts of hypercortisolism, including unresolved comorbidities and increased mortality risk, the consequences of delayed diagnosis, and how the understanding of its clinical presentation has evolved.

Experts discuss the physical impact of hypercortisolism on a patient, how the condition affects overall health, and the long-term risks that remain even after remission, including incomplete resolution of comorbidities, reduced quality of life, and increased mortality risk.

Experts discuss practical strategies for identifying and screening for hypercortisolism.

Panelists discuss how treating hypercortisolism in patients may have long-term effects on glycemic control and overall health, potentially influencing future standards of care for difficult-to-control Type 2 diabetes, while emphasizing the need for clinicians to carefully manage such patients as ongoing research continues.

Experts discuss the CATALYST study's evaluation of mifepristone for hypercortisolism patients with hard-to-manage type 2 diabetes, its mechanism of action, suitable patient populations, treatment approaches for those with adrenal tumors, and factors determining surgical candidacy.

Key opinion leaders explore the diverse clinical manifestations of hypercortisolism across its spectrum of presentations.

Medical experts explore why findings from this study are crucial for clinicians managing diabetes, particularly those in primary care settings, and how these insights can impact their approach to patient care.

Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.

The panel of medical experts discuss the prevalence of hypercortisolism based on the CATALYST trial.

The expert panel analyze data from the CATALYST trial.

Key opinion leaders navigate challenges associated with diabetes management.

The CATALYST study is discussed by a panel of experts led by Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES.